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Transfusion independence and survival in patients with acute myeloid leukemia treated with 5-azacytidine
Reanalysis of the CALGB (1) and AZA001 (2) studies in advanced myelodysplastic syndrome (MDS) suggests that 5-azacytidine (AZA) is effective for acute myeloblastic leukemia (AML) with <30% bone marrow blasts. Most AML patients are elderly (>65 years old) and unfit for intensive chemotherapy and allogeneic transplantation (3); prognosis is dreadful with median survival of a few months (4) . For these patients appropriate treatments are best supportive care or low dose cytarabine (3).
Compared with best supportive care, low-dose cytarabine more frequently induces complete remissions (18% vs 1%) and prolongs survival (3.8 vs 2.5 months) (3). AZA targets DNA methyltransferase and reactivates quiescent genes (5), decreases leukemic cell proliferation and induces cell differentiation. In higher risk MDS or in AML with <30% bone marrow blasts (6), AZA outperformed conventional care (best supportive care, low-dose cytarabine, and intensive chemotherapy) (7) with longer hematologic improvement and transfusion independence (TI) (5) . Here, we postulated that patients unfit for standard AML chemotherapy might also benefit from AZA, irrespectively of bone marrow blast count.
We systematically reviewed charts of all patients treated with AZA at our institution between January 1 st 2007 and December 31 st 2011, and identified 52 consecutive AML patients. These patients were not eligible for intensive chemotherapy due to advanced age (n=33) or comorbidities (n=9), or were refractory to initial intensive chemotherapy (n=10). AZA was administered at 100mg/m 2 sc day 1-5, over 28-day cycles. This schedule is equivalent to standard day 1-7 MDS treatment (8) and allows weekday outpatient treatment (2) . Therapy was continued until disease progression, as survival benefit is extended beyond achievement of best response (9) . Indication At baseline, 15% (n=9) of our patients had RBC-TI and 25% (n=13) PLT-TI. Median overall survival of the 52 enrolled patients was 8.6 months and 12-month survival rate was 28% [95CI 15-43%]. We excluded 14 patients from transfusion and survival analyses, since they did not reach the minimal 8-week observation period. Among them, 11 patients received only 1 cycle of AZA and 3 received 2 cycles. Treatment was interrupted due to premature death or disease progression (n=12), or availability of a donor for allogeneic stem cell transplantation (n=2). Among these 14 patients, 3
had RBC-TI and 3 had PLT-TI at the onset of therapy. Median OS was 1.3 months
Characteristics of the 38 remaining patients are presented in Table 1 . Patients with baseline or acquired RBC-TI (n=22) were grouped and compared to patients that never reached RBC-TI (n=16). Among patients with transfusion independence, 6 had RBC-TI at baseline while 16 achieved RBC-TI under therapy. Except for age, which was older for patients with RBC-TI, we found no differences in baseline characteristics. Our 38 patients received a median of 6 [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] cycles of AZA. Overall response rate was 23% (n=9), distributed in 7 complete response with incomplete blood count recovery (CRi) and 2 partial remission (PR) (10) . The residual 29 patients exhibited resistant disease (RD, 76%). RD status was equally distributed among transfusion independent and transfusion dependent groups (13 vs 16).
RBC-TI at baseline or under AZA therapy (n=22) was associated to prolonged survival. The median OS of transfusion independent patients was 11.1 months vs. The impact of PLT-TI on survival was similar, although not significant (OS 10.7 vs. In conclusion, we report here for the first time that AZA can induce transfusion independence in half of previously transfusion dependent patients and that transfusion independence is a strong prognostic factor in unfit AML patients. SB, OS and MAD contributed to study design, data interpretation, and writing.
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